Thermo Fisher Scientific (TMO) reported $12.14 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 9.1%. EPS of $6.68 for the same period compares to $5.79 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $11.92 billion, representing a surprise of +1.81%. The company delivered an EPS surprise of +4.38%, with the consensus EPS estimate being $6.40.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue Growth - Organic: 6% compared to the 4.3% average estimate based on four analysts. Revenues- Laboratory Products and Biopharma Services: $6.86 billion versus $6.56 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15% change. Revenues- Specialty Diagnostics: $1.1 billion versus the four-analyst average estimate of $1.14 billion. The reported number represents a year-over-year change of -6.5%. Revenues- Life Sciences Solutions: $2.72 billion compared to the $2.85 billion average estimate based on four analysts. The reported number represents a change of +5.1% year over year. Revenues- Eliminations: $-546 million versus the four-analyst average estimate of $-539.74 million. The reported number represents a year-over-year change of +8.6%. Revenues- Analytical Instruments: $2 billion compared to the $1.95 billion average estimate based on four analysts. The reported number represents a change of +5.8% year over year.View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have returned +4.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).